Adrenal News

Adults with primary aldosteronism had improvements in disease severity after undergoing an adrenalectomy, according to findings published in Endocrine Practice.

The FDA has granted priority review designation for two new drug applications for a selective corticotropin-releasing factor type 1 receptor to treat congenital adrenal hyperplasia, according to a press release.

ORLANDO — Nearly one-quarter of adults with difficult-to-control type 2 diabetes also have hypercortisolism, and treating hypercortisolism may also benefit glycemic control in those with both conditions, according to speakers.

PHILADELPHIA — Adults with Cushing’s syndrome who responded to relacorilant had sustained improvements in blood pressure and glucose levels through 34 weeks, according to findings from a phase 3 trial.

BOSTON — In this video exclusive, Maria Fleseriu, MD, FACE, discusses some of the top adrenal and pituitary news from ENDO 2024.

BOSTON —In this video exclusive, Richard J. Auchus, MD, PhD, describes a possible new treatment paradigm for congenital adrenal hyperplasia with crinecerfont, an investigational drug granted a breakthrough designation in December.

BOSTON — In the first year after stopping anabolic steroid misuse, men had worse sexual function than those who continued using or never used the agents as well as more depression and anxiety, according to a presenter at ENDO 2024.

BOSTON — Crinecerfont lowered androstenedione levels and allowed for lower glucocorticoid doses for children with classic congenital adrenal hyperplasia, according to findings from the CAHtalyst Pediatric phase 3 trial.

BOSTON — Adults with congenital adrenal hyperplasia receiving an oral nonsteroidal treatment saw a marked reduction in daily glucocorticoid dose at 24 weeks with maintenance of androgen control compared with placebo, researchers reported.